BioMarin

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. 

CEO
Alexander Hardy
CEOAlexander Hardy
Employees
3,040
Employees3,040
Headquarters
San Rafael, California
HeadquartersSan Rafael, California
Founded
1997
Founded1997
Employees
3,040
Employees3,040

BMRN Key Statistics

Market cap
10.74B
Market cap10.74B
Price-Earnings ratio
20.96
Price-Earnings ratio20.96
Dividend yield
Dividend yield
Average volume
3.81M
Average volume3.81M
High today
$56.05
High today$56.05
Low today
$55.03
Low today$55.03
Open price
$55.77
Open price$55.77
Volume
1.17M
Volume1.17M
52 Week high
$73.51
52 Week high$73.51
52 Week low
$50.76
52 Week low$50.76

Stock Snapshot

As of today, BioMarin(BMRN) shares are valued at $55.93. The company's market cap stands at 10.74B, with a P/E ratio of 20.96.

On 2025-12-01, BioMarin(BMRN) stock moved within a range of $55.03 to $56.05. With shares now at $55.93, the stock is trading +1.6% above its intraday low and -0.2% below the session's peak.

Trading volume for BioMarin(BMRN) stock has reached 1.17M, versus its average volume of 3.81M.

Over the past 52 weeks, BioMarin(BMRN) stock has traded between a high of $73.51 and a low of $50.76.

Over the past 52 weeks, BioMarin(BMRN) stock has traded between a high of $73.51 and a low of $50.76.

BMRN News

Simply Wall St 6d
Will BioMarin’s Raised Outlook After Solid Revenue Growth Shift Its Investment Narrative?

BioMarin Pharmaceutical recently presented at the Jefferies London Healthcare Conference 2025 in London, following its announcement of a 4.1% year-over-year rev...

Will BioMarin’s Raised Outlook After Solid Revenue Growth Shift Its Investment Narrative?

Analyst ratings

79%

of 29 ratings
Buy
79.3%
Hold
20.7%
Sell
0%

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.